Blogs

The European Medicines Agency (EMA) moved this week to place new restrictions on the business consulting activities of its former director, Thomas Lönngren. Lönngren’s industry consulting prompted criticism after he left the agency in December. While EMA’s statement formally approves its ex-chief’s  consulting to date, saying there has been no misuse of confidential information or risk of undue influence on agency decisions, it also limits Lönngren’s activities for the next two years. Those limits include a prohibition on taking executive pharmaceutical industry positions, restrictions on providing advice on EMA-regulated products and limiting professional contact with EMA staff or committee members.

EMA Limits Former Director Over Consulting Gig (Pharmalot)

Ex-EMA chief's pharma consulting plans reined in (FiercePharma)

EMA puts curbs on new work by ex-chief Lonngren (Pharma Times)

Activities of former EMA Executive Director Thomas Lönngren (EMA press release)